Trial Profile

A Phase I Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2, a Genetically Engineered HSV-1 Virus, and Immunomodulation With Cyclophosphamide

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 16 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CAN 3110 (Primary) ; Cyclophosphamide
Indications Anaplastic astrocytoma; Glioblastoma; Glioma; Oligodendroglioma
Focus Adverse reactions; First in man
Acronyms rQNestin

Most Recent Events

08 Jul 2025 Planned End Date changed from 1 Jun 2026 to 1 Jan 2027.
08 Jul 2025 Planned primary completion date changed from 1 Jun 2025 to 1 Jan 2026.
13 Jan 2025 According to a Candel Therapeutics media release, company on track to report overall survival data in patients with recurrent high-grade glioma (rHGG) from ongoing phase 1b trial evaluating multiple doses of CAN-3110, expected in Q4 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com